BIOLINERX RAISES AN ADDITIONAL $9 MILLION AND ADVANCES PIPELINE OF DRUG CANDIDATES TOWARD CLINICAL TRIALS

BioLineRx, Israel's leading specialized drug development company, today announced that current investors Giza Venture Capital, Pitango Venture Capital and Teva Pharmaceuticals Industries Ltd. have committed an additional $9 million in funding to the company. The $9 million follow-on investment is on top of the original founders' commitment of approximately $14 million, which also included Hadasit, Star Ventures, and the Jerusalem Development Authority, and is supplemented by the $21 million Israeli National Biotech Initiative grant that BioLineRx received in November of last year.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050926005501&newsLang=en)